Egrifta tesamorelin regulatory update

Theratechnologies said it submitted to Health Canada a request for reconsideration of the agency's notice of non-compliance-withdrawal for an NDS for Egrifta tesamorelin to treat excess abdominal fat in HIV-infected patients with lipodystrophy. Health Canada issued the notice last month concluding that the risks of tesamorelin outweigh its benefits for the indication (see BioCentury, March 18). ...